Altimmune Inc. (NASDAQ: ALT) stock show a rise of about 9.49% during premarket after Alt announced its additional preclinical data for its single-dose intranasal Covid-19 vaccine candidate AdCovid. It is basically designed to stimulate a wide immune response that includes both systematic immunity and local immunity in the nasal cavity and respiratory tract. Altimmune is a biopharmaceutical clinical-stage company that focuses on the development of intranasal vaccines, immune-modulating therapies, and treatments for liver diseases.
The preclinical data has been collected after the studies conducted at Altimmune’s collaborating institutions for the single dose intranasal COVID-19 vaccine AdCOVID. The data obtained under the supervision of James Brien PhD and Amelia Pinto PhD in the department of Molecular Biology and immunology at SLU shows that all the animals which received AdCOVID survived with no weight loss. Whereas the data received in the K18-hACE2 transgenic mouse model showed a single dose of intranasal AdCOVID gave 100% protection against SARS-CoV-2 virus.
In another study that took place at UAB under the supervision of Dr. Frances in his laboratory conducted on the same animal model, the results showed that a single intranasal dose of AdCOVID happened to cause a greater that 1000-fold decrease in replicating virus in the nasal cavity and respiratory tract following infection with SARS-CoV-2.
Assistant Professor of Molecular Microbiology and immunology at SLU said that these results are very considerable and eminent. These results show that AdCovid not only provide protection against COVID-19 related deaths but also against any sort of infection in the mice.
This recent development by Altimmune Inc. is definitely company’s great achievement including the sustainability of AdCOVID at room temperature which would allow the cold-chain free shipment of the vaccine. Altimmune believes that the promising results obtained for AdCOVID vaccine and its easy handling methods combined with the potential to block SARS-CoV-2 transmission will place AdCOVID at the position leading intranasal COVID-19 vaccine.